TABLE 1.
Baseline characteristics of included literatures.
| Study | Type of patients | Sample Size | Age (years, mean±SD) |
Gender (male/female) |
Drugs | Follow-up (months) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control | Intervention | Control | ARNI | Control | Intervention | Control | Initial time | |||
| Chen et al. (2019) | AMI PPCI HF | 26 | 26 | 56.3 ± 10.1 | 55.7 ± 9.7 | 15/11 | 14/12 | sacubitril–valsartan 200 mg bid | Enalapril 5 mg qd |
In 2 weeks after PPCI | 6 |
| Chen et al. (2020) | AMI PPCI HFrEF | 30 | 30 | 55.4 ± 10.1 | 54.6 ± 10.3 | 15/15 | 15/15 | Sacubitril–valsartan MTD | Enalapril MTD |
After PPCI | 6 |
| Wang et al. (2020) | STEMI PPCI HFrEF | 80 | 80 | 59.0 ± 10.3 | 58.0 ± 10.4 | 69/11 | 67/13 | Sacubitril–valsartan MTD | Valsartan MTD |
In 1 week after PPCI | 6 |
| Zhao (2020) | STEMI PPCI HFrEF | 62 | 61 | 68.2 ± 2.4 | 68.4 ± 2.3 | 39/23 | 40/21 | Sacubitril–valsartan MTD | Valsartan MTD |
In 1 week after PPCI | 6 |
| Li et al. (2020) | AMI PPCI | 50 | 50 | 54.4 ± 5.9 | 54.9 ± 6.1 | 28/22 | 27/23 | Sacubitril–valsartan 200 mg bid | Enalapril 10 mg bid |
After PPCI | 6 |
| Dong et al. (2020) | STEMI PPCI HFrEF | 40 | 40 | 63.9 ± 8.2 | 62.0 ± 7.6 | 23/17 | 26/14 | Sacubitril–valsartan 200 mg bid | Valsartan 80 mg qd |
After PPCI | 6 |
| Zhao et al. (2020) | AMI PPCI HFrEF | 45 | 45 | 62.8 ± 3.9 | 63.2 ± 4.6 | 25/20 | 27/18 | Sacubitril–valsartan 50 mg bid | Valsartan 80 mg qd |
In 24 h after PPCI | 3 |
| Wang et al. (2020) | STEMI PPCI HFrEF | 68 | 69 | 59.1 ± 7.2 | 60.6 ± 7.6 | 52/16 | 54/15 | Sacubitril–valsartan 100 mg bid | Enalapril 5 mg bid |
After PPCI | 6 |
| Zhang et al. (2021a) | STEMI PPCI | 79 | 77 | 60.3 ± 11.7 | 60.0 ± 10.9 | 59/20 | 55/22 | Sacubitril–valsartan MTD | Perindopril MTD |
In 24 hours after PPCI | 6 |
| Rezq et al. (2021) | STEMI PPCI | 100 | 100 | 52.0 ± 9.2 | 57.0 ± 11.6 | 86/14 | 88/12 | Sacubitril–valsartan 100 mg bid | Ramipril 5 mg bid |
After PPCI | 6 |
| Zhang et al. (2021a) | AMI PPCI HFrEF | 43 | 43 | 48.6 ± 10.4 | 49.8 ± 7.2 | 35/8 | 37/6 | Sacubitril–valsartan 200 mg bid | Benazepril 10 mg qd |
After PPCI | 3 |
| Chen (2021) | AMI PPCI HFrEF | 31 | 30 | 56.3 ± 10.1 | 55. 7 ± 9.7 | 16/15 | 17/13 | Sacubitril–valsartan 100 mg qd | Enalapril 5 mg qd |
After PPCI | 1 |
| Zhang et al. (2021c) | AMI PPCI | 56 | 67 | 51.9 ± 3.4 | 52.8 ± 3.3 | 36/20 | 39/18 | Sacubitril–valsartan 200 mg bid | Enalapril 20 mg qd |
After PPCI | 6 |
| Yang et al. (2021) | AMI PPCI | 38 | 38 | 60.0 ± 13.0 | 55.0 ± 12.0 | 31/7 | 35/3 | Sacubitril–valsartan 100 mg bid | Valsartan 80 mg qd |
After PPCI | 3 |
| Gu (2021) | AMI PPCI HF | 40 | 40 | 62.2 ± 5.4 | 62.2 ± 4.5 | 24/16 | 22/18 | Sacubitril–valsartan MTD | Valsartan MTD |
After PPCI | 6 |
| Fu and Xu (2022) | STEMI PPCI HFrEF | 63 | 63 | 64.1 ± 9.1 | 67.4 ± 11.5 | 44/19 | 47/16 | Sacubitril–valsartan 200 mg bid | Fosinopril 40 mg qd |
After PPCI | 6 |
| Li and Xiong (2022) | STEMI PPCI HFrEF | 50 | 48 | 62.4 ± 9.8 | 62.7 ± 10.1 | 27/23 | 26/22 | Sacubitril–valsartan 200 mg bid | Perindopril MTD |
after PPCI | 6 |
| Liu et al. (2022) | AMI PPCI | 165 | 183 | 58.1 ± 10.2 | 58.0 ± 11.7 | 129/36 | 150/33 | Sacubitril–valsartan 200 mg bid | Ramipril 10 mg qd |
After PPCI | 6 |
| Yang et al. (2022b) | STEMI PPCI HFrEF | 48 | 47 | 55.8 ± 11.4 | 56.2 ± 10.9 | 41/7 | 38/9 | Sacubitril–valsartan MTD | Valsartan MTD |
After PPCI | 6 |
| Ma and Yang (2022) | AMI PPCI HFrEF | 30 | 30 | 62.4 ± 5.6 | 63.3 ± 6.1 | 18/12 | 16/14 | Sacubitril–valsartan 200mg bid | Enalapril/ valsartan MTD |
After PPCI | 6 |
| Dong et al. (2022) | STEMI PPCI | 65 | 66 | 60.2 ± 9.8 | 60.4 ± 10.0 | 51 | 53 | Sacubitril–valsartan 200 mg bid | Enalapril 10 mg bid |
In 24 h after PPCI | 6 |
Notes: AMI, acute myocardial infraction; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; PPCI, Primary percutaneous coronary intervention; MTD, maximum tolerated dose; SD, standard deviation; STEMI, ST segment elevation myocardial infarction.